Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67359 | 0.85 | ACHE (0.41) | ACHEHTTCYP1A2NFE2L2HPGD | |
| SCHEMBL29371061 | 0.85 | ACHE (0.41) | ACHEHTTCYP1A2NFE2L2HPGD | |
| SCHEMBL175646 | 0.85 | ACHE (0.41) | ACHEHTTCYP1A2NFE2L2HPGD | |
| 1,2-Dichlorobenzene SCHEMBL19179804 | 0.80 | TSHR (0.43) | ACHETSHRLMNAHTTCYP1A2 | |
| Methylene Chloride SCHEMBL15412127 | 0.76 | ACHE (0.35) | ACHEHTTHPGDCES2CES1 | |
| Chloroform SCHEMBL1547931 | 0.76 | ACHE (0.35) | ACHEHPGDCES2CES1PTGS2 | |
| Toluene SCHEMBL21412786 | 0.75 | ACHE (0.69) | ACHETSHRLMNAALOX12CYP1A2 | |
| SCHEMBL30064 | 0.74 | ACHE (0.42) | ACHETSHRHTTCYP1A2HPGD | |
| Toluene SCHEMBL4307943 | 0.73 | ACHE (0.79) | ACHETSHRLMNAALOX12NFE2L2 | |
| Toluene SCHEMBL4535818 | 0.71 | ACHE (1.00) | ACHETSHRLMNAALOX12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | claimed |
| EP-2224920-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2010-09-08 | — | — | EP | claimed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | claimed |
| WO-2009073780-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | claimed |
| EP-3736138-B1 | MULTI-LAYER IMAGING BLANKET AND VARIABLE DATA LITHOGRAPHY SYSTEM | XEROX CORP (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4126862-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11230135-B2 | Multi-layer imaging blanket | XEROX CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021202688-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200353770-A1 | MULTI-LAYER IMAGING BLANKET | XEROX CORPORATION (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3736138-A1 | MULTI-LAYER IMAGING BLANKET | Xerox Corporation (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20190322114-A1 | MULTI-LAYER BLANKET | XEROX CORPORATION | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | ACHE 1387/4885TSHR 3416/4885LMNA 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.